Vestal Point Capital LP Increases Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Vestal Point Capital LP lifted its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 4.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,180,000 shares of the biotechnology company's stock after purchasing an additional 180,000 shares during the period. Astria Therapeutics comprises approximately 2.2% of Vestal Point Capital LP's holdings, making the stock its 16th biggest holding. Vestal Point Capital LP owned 7.41% of Astria Therapeutics worth $37,369,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of ATXS. Fcpm Iii Services B.V. purchased a new position in shares of Astria Therapeutics during the 4th quarter worth approximately $25,680,000. Raymond James Financial Inc. acquired a new position in Astria Therapeutics in the 4th quarter valued at $707,000. Patient Square Capital LP lifted its stake in shares of Astria Therapeutics by 166.5% during the 4th quarter. Patient Square Capital LP now owns 105,057 shares of the biotechnology company's stock worth $939,000 after purchasing an additional 65,635 shares during the period. Voya Investment Management LLC lifted its stake in shares of Astria Therapeutics by 367.4% during the 4th quarter. Voya Investment Management LLC now owns 71,708 shares of the biotechnology company's stock worth $641,000 after purchasing an additional 56,366 shares during the period. Finally, DAFNA Capital Management LLC lifted its stake in shares of Astria Therapeutics by 17.9% during the 4th quarter. DAFNA Capital Management LLC now owns 299,775 shares of the biotechnology company's stock worth $2,680,000 after purchasing an additional 45,610 shares during the period. 98.98% of the stock is owned by hedge funds and other institutional investors.

Astria Therapeutics Stock Down 3.9%

Shares of NASDAQ ATXS traded down $0.16 during trading on Friday, hitting $3.92. 245,437 shares of the company traded hands, compared to its average volume of 371,487. Astria Therapeutics, Inc. has a 1 year low of $3.56 and a 1 year high of $12.92. The company has a 50-day moving average price of $4.75 and a 200-day moving average price of $7.14. The firm has a market capitalization of $221.22 million, a P/E ratio of -1.88 and a beta of 0.45.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.10). Research analysts predict that Astria Therapeutics, Inc. will post -1.65 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ATXS has been the topic of a number of recent analyst reports. Cantor Fitzgerald reissued an "overweight" rating and set a $47.00 price target on shares of Astria Therapeutics in a research note on Wednesday, May 14th. JMP Securities initiated coverage on Astria Therapeutics in a research note on Friday, January 31st. They set an "outperform" rating and a $26.00 price target on the stock. Wedbush reissued an "outperform" rating and set a $28.00 price target (up previously from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. Citizens Jmp raised Astria Therapeutics to a "strong-buy" rating in a research note on Friday, January 31st. Finally, HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, March 11th. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $30.00.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.